Tech Company Financing Transactions
Seaport Therapeutics Funding Round
General Atlantic, Arch Venture Partners and CPP Investments invested in a $225 million Series B capital raise for Seaport Therapeutics. This venture round was announced on 10/21/2024.
Transaction Overview
Company Name
Announced On
10/21/2024
Transaction Type
Venture Equity
Amount
$225,000,000
Round
Series B
Investors
Proceeds Purpose
Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines through important clinical milestones as well as further advance the capabilities of the Glyph� technology platform, which has demonstrated clinical proof-of-concept.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
6 Tide Street 400
Seaport Boston, MA 02210
USA
Seaport Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Powered by our Glyph platform we are advancing first and best-in-class medicines for people living with neuropsychiatric disorders. We have a proven strategy of advancing clinically validated mechanisms -- previously held back by limitations -- which our technology platform can now overcome.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daphne Zohar
Founder
Steven Paul
Browse more venture capital transactions:
Prev: 10/20/2024: Biological Lattice Industries venture capital transaction
Next: 10/21/2024: Conflux Technology venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs